Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 20802498.
- Also identified by DOI 10.1038/nm.2203.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, accompanied by an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites on the HIV-1 envelope gp120 subunit. The enhanced neutralization resistance of HIV-1 in contemporary seroconverters coincided with the poorer elicitation of neutralizing antibody responses, which may have implications for vaccine design.
Medical subject headings
- AIDS Vaccines
- AIDS Vaccines/immunology
- AIDS Vaccines/therapeutic use
- Antibody Formation
- Antibody Formation/immunology
- Genetic Variation
- HIV
- HIV/genetics
- HIV/immunology
- HIV Antibodies
- HIV Antibodies/immunology
- HIV Envelope Protein gp120
- HIV Envelope Protein gp120/genetics
- HIV Envelope Protein gp120/immunology
- HIV Infections
- HIV Infections/immunology
- Humans
- Immunity, Humoral
- Immunoglobulins, Intravenous
- Immunoglobulins, Intravenous/immunology
- Immunoglobulins, Intravenous/therapeutic use
- Neutralization Tests
- Viral Envelope Proteins
- Viral Envelope Proteins/genetics
- Viral Envelope Proteins/immunology
- Viral Envelope Proteins/metabolism